There is growing number of retrospective studies showing that immune-related biomarkers have prognostic value in ER + BC beyond higher TILs, including poor outcomes associated with higher tumour infiltration of immunosuppressive FOXP3+ Tregs and higher expression of negative regulators of T-cell immune functions, such as CTLA4 and PD-L1. This evidence concerns the gene FOXP3 and breast cancer.